Aspira Women's Health (AWH) 10-K 31 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 29, 2021	Jun. 30, 2020
Document And Entity Information [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Document Transition Report	false
Current Fiscal Year End Date	--12-31
Entity File Number	001-34810
Entity Registrant Name	Aspira Women's Health Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-0595156
Entity Address, Address Line One	12117 Bee Caves Road
Entity Address, Address Line Two	Building III
Entity Address, Address Line Three	Suite 100
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78738
City Area Code	512
Local Phone Number	519-0400
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	AWH
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 290,267,539
Entity Common Stock, Shares Outstanding		111,716,852
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Central Index Key	0000926617
Amendment Flag	false
Documents Incorporated by Reference	Certain information from the registrant’s definitive Proxy Statement for its Annual Meeting of Stockholders is incorporated by reference into Part III of this report. The registrant intends to file the Proxy Statement with the Securities and Exchange Commission within 120 days of December 31, 2020.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 16,631	$ 11,703
Accounts receivable	865	924
Prepaid expenses and other current assets	1,077	758
Inventories	30	25
Total current assets	18,603	13,410
Property and equipment, net	583	353
Right-of-use assets	406	52
Other assets	13	13
Total assets	19,605	13,828
Current liabilities:
Accounts payable	1,149	855
Accrued liabilities	3,618	2,588
Current portion long-term debt	999	193
Short-term debt	611	303
Lease liability	23	39
Total current liabilities	6,400	3,978
Non-current liabilities:
Long-term debt	3,077	1,099
Lease liability	409	13
Total liabilities	9,886	5,090
Commitments and contingencies (Notes 3 and 6)
Stockholders' equity:
Common stock, par value $0.001 per share, 150,000,000 shares authorized at December 31, 2020 and December 31, 2019; 104,619,876 and 97,286,157 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively	105	97
Additional paid-in capital	449,680	430,802
Accumulated deficit	(440,066)	(422,161)
Total stockholders' equity	9,719	8,738
Total liabilities and stockholders' equity	$ 19,605	$ 13,828

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Consolidated Balance Sheets [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	104,619,876	97,286,157
Common stock, shares outstanding	104,619,876	97,286,157

Consolidated Statements Of Oper

Consolidated Statements Of Operations - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Revenue:
Revenue		$ 4,651	$ 4,538
Cost of revenue:
Cost of revenue	[1]	3,415	3,343
Gross profit		1,236	1,195
Operating expenses:
Research and development	[1]	2,104	1,018
Sales and marketing	[1]	8,843	9,645
General and administrative	[1]	8,270	5,810
Total operating expenses		19,217	16,473
Loss from operations		(17,981)	(15,278)
Interest income, net		10	59
Other income (expense), net		66	(18)
Net loss		$ (17,905)	$ (15,237)
Net loss per share - basic and diluted		$ (0.18)	$ (0.18)
Weighted average common shares used to compute basic and diluted net loss per common share		100,723,303	86,595,581
Product [Member]
Revenue:
Revenue		$ 4,530	$ 4,404
Cost of revenue:
Cost of revenue	[1]	2,500	2,378
Genetics [Member]
Revenue:
Revenue		108	22
Cost of revenue:
Cost of revenue	[1]	898	295
Service [Member]
Revenue:
Revenue		13	112
Cost of revenue:
Cost of revenue	[1]	$ 17	$ 670
[1]	Non-cash stock-based compensation expense included in cost of revenue and operating expenses

Consolidated Statements Of Op_2

Consolidated Statements Of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cost Of Revenue [Member]
Stock-based compensation expense	$ 106	$ 78
Research And Development [Member]
Stock-based compensation expense	34	4
Sales And Marketing [Member]
Stock-based compensation expense	228	125
General And Administrative [Member]
Stock-based compensation expense	$ 1,180	$ 986

Consolidated Statements Of Chan

Consolidated Statements Of Changes In Stockholders' Equity - USD ($) $ in Thousands	Public Offering Exercise Of Underwriter's Option [Member]Common Stock [Member]	Public Offering Exercise Of Underwriter's Option [Member]Additional Paid-In Capital [Member]	Public Offering Exercise Of Underwriter's Option [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance (in shares) at Dec. 31, 2018				75,501,394
Balance at Dec. 31, 2018				$ 75	$ 414,001	$ (406,924)	$ 7,152
Net loss						(15,237)	$ (15,237)
Common stock issued in conjunction with exercise of stock options (in shares)				19,687			19,687
Common stock issued in conjunction with exercise of stock options					17		$ 17
Common stock issued in conjunction with public offering, net of issuance costs (in shares)	2,812,500			18,750,000
Common stock issued in conjunction with public offering, net of issuance costs	$ 3	$ 2,089	$ 2,092	$ 19	13,502		13,521
Common stock issued for restricted stock awards (in shares)				202,576
Common stock issued for restricted stock awards					250		250
Stock compensation charge					943		943
Balance (in shares) at Dec. 31, 2019				97,286,157
Balance at Dec. 31, 2019				$ 97	430,802	(422,161)	8,738
Net loss						(17,905)	$ (17,905)
Common stock issued in conjunction with exercise of stock options (in shares)				1,105,675			1,105,675
Common stock issued in conjunction with exercise of stock options				$ 1	1,636		$ 1,637
Common stock issued for restricted stock awards (in shares)				267,706
Common stock issued for restricted stock awards					182		182
Stock compensation charge					1,366		1,366
Common stock issued in conjunction with warrant exercises (in shares)				2,810,338
Common stock issued in conjunction with warrant exercises				$ 4	5,056		5,060
Common stock issued in conjunction with private placement, net of issuance costs, (in shares)				3,150,000
Common stock issued in conjunction with private placement, net of issuance costs				$ 3	10,638		10,641
Balance (in shares) at Dec. 31, 2020				104,619,876
Balance at Dec. 31, 2020				$ 105	$ 449,680	$ (440,066)	$ 9,719

Consolidated Statements Of Ch_2

Consolidated Statements Of Changes In Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Private Placement [Member]
Stock issued, issuance costs	$ 384
Public Offering Of Common Stock [Member]
Stock issued, issuance costs		$ 1,480
Public Offering Exercise Of Underwriter's Option [Member]
Stock issued, issuance costs		$ 158

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (17,905)	$ (15,237)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash lease expense	26
Depreciation and amortization	265	333
Stock-based compensation expense	1,548	1,193
Loss on sale and disposal of property and equipment	3	55
Changes in operating assets and liabilities:
Accounts receivable	59	(138)
Prepaid expenses and other assets	(319)	(209)
Inventories	(5)	67
Accounts payable, accrued liabilities and other liabilities	1,594	971
Net cash used in operating activities	(14,734)	(12,965)
Cash flows from investing activities:
Purchase of property and equipment	(490)	(133)
Net cash used in investing activities	(490)	(133)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs		13,521
Proceeds from issuance of common stock in conjunction with the exercise of the underwriter’s option to purchase additional shares in connection with a public offering, net of issuance costs		2,092
Principal repayment of DECD loan	(191)	(189)
Proceeds from issuance of common stock from exercise of stock options	1,637	17
Proceeds from DECD loan	2,000
Proceeds from PPP loan	1,005
Proceeds from exercise of warrants	5,060
Proceeds from private placement, net of issuance costs	10,641
Net cash provided by financing activities	20,152	15,441
Net increase in cash and cash equivalents	4,928	2,343
Cash and cash equivalents, beginning of period	11,703	9,360
Cash and cash equivalents, end of period	16,631	11,703
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	37	38
Supplemental disclosure of noncash investing and financing activities:
Net increase in right-of-use assets	354	$ 52
Net changes in accounts payable related to capital expenditures	$ 8

Basis Of Presentation And Summa

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies	12 Months Ended
	Dec. 31, 2020
Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies [Abstract]
Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies	NOTE 1: Basis of Presentation and Summary of Significant Accounting and Reporting Policies  Organization and Basis of Presentation  Aspira Women’s Health Inc., formerly known as Vermillion, Inc. (“Aspira” and its wholly-owned subsidiaries are collectively referred to as the “Company ” ) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company currently markets and sells the following products and related services: (1) OVA1, a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at high - risk of having a malignant ovarian tumor prior to planned surgery; (2) OVERA, a second-generation biomarker panel intended to maintain our product’s high sensitivity while improving specificity; (3) OVA1plus, a service offering combining our OVA1 and OVERA products, designed to improve accuracy and reduce false elevations in the intermediate risk area by leveraging the strengths of OVA1’s (MIA) sensitivity and OVERA’s (MIA2G) specificity; (4) Aspira GenetiX, a genetic test for gynecologic cancer risk, with a core focus on female reproductive cancers, including breast, ovarian, endometrial, uterine and cervical cancers ; and (5) Aspira Synergy, the Company’s new decentralized platform and cloud service technology. T hrough December 31, 2020, the Company’s product and related services revenue was limited to revenue generated by sales of OVA1, OVA1plus and Aspira GenetiX . The Company sells OVA1 and OVA1plus through Aspira’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, Aspira Labs, Inc. (“ASPiRA LABS”).  The Company has historically also offered in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which commenced operations in June 2016. ASPiRA IVD was a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays. The Company has discontinued pursuing contracts for ASPiRA IVD and its contractual commitments were largely concluded in the fourth quarter of 2019 .  Effective January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-02, Leases (“ASU 2016-02”), and elected the package of practical expedients, including the hindsight practical expedient and the new transition approach permitted by ASU No. 2018-11, Leases, Targeted Improvements (“ASU 2018-11”). The standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2018-11 allows the Company not to reassess existing identification of leases, classification of leases or any initial direct costs. The Company has two office leases, one of which has as lease less than 12 months. The Company recognized ROU assets and a lease liability of approximately $178,000 related to its leases on its consolidated balance sheet as of January 1, 2019. The Company did no t have a cumulative adjustment impacting retained earnings.  Effective January 1, 2020, the Company adopted FASB ASU No. 2018-15, Intangibles-Goodwill and Other-Internal Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , using the prospective transition approach, which allows the Company to change the accounting method without restating prior periods or booking cumulative adjustments . ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The adoption of ASU 2018-15 did not have a material impact on the consolidated financial statements.  Liquidity  The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $440,066,000 and had limited liquidity at December 31, 2020. The Company also expects to incur a net loss and negative cash flows from operations for 2021.  In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China. The novel coronavirus has since spread to over 100 countries, including every state in the United States. In March 2020, the World Health Organization declared COVID-19, the disease caused by the novel coronavirus, a pandemic, and the United States declared a national emergency with respect to the coronavirus outbreak. This outbreak has severely impacted global economic activity, and many countries and many states in the United States have reacted to the outbreak by instituting quarantines, mandating business and school closures and restricting travel. In addition, many conventions and industry conferences have been canceled.  As a result of the COVID-19 pandemic and actions taken to contain it, the Company’s test volume, and resulting revenue, decreased significantly in late March and the full month of April 2020 as fewer patients visited their physicians and elective surgeries were postponed as a result of closures. The Company saw some increases in its test volume towards the latter half of the second quarter and in the third quarter of 2020, and test volume trended back to pre-COVID-19 levels during the late third quarter 2020. In order to reduce the impact of limitations on visiting physician offices due to closures and quarantines, the Company implemented other mechanisms for reaching physicians such as virtual sales representative meetings and increased digital sales and marketing. E nrollment for future studies has been slower than originally planned due to the impact of current closures for some states. The full impact of the COVID-19 pandemic continues to evolve as of the date of this filing. As a result, the Company is unable to estimate the extent of the impact of the COVID-19 pandemic on its liquidity.  As discussed in Note 6, in March 2016, the Company entered into a loan agreement (as amended on March 7, 2018 and April 3, 2020, the “Loan Agreement”) with the State of Connecticut Department of Economic and Community Development (the “DECD”), pursuant to which it may borrow up to $4,000,000 from the DECD.  The loan may be prepaid at any time without premium or penalty. An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. On December 3, 2020, the Company received a disbursement of the remaining $2,000,000 under the Loan Agreement, as the Company had we achieved the target employment milestone necessary to receive an additional $1,000,000 under the Loan Agreement and the DECD determined to fund the remaining $1,000,000 under the Loan Agreement after concluding that the required revenue target would likely have been achieved in the first quarter of 2020 in the absence of the impacts of COVID-19.  As discussed in Note 7, on June 28, 2019, the Company completed a public offering (the “2019 Offering”), pursuant to which certain investors purchased Aspira common stock for net proceeds of approximately $13,521,000 after deducting underwriting discounts, commissions and other expenses related to the 2019 Offering. On July 2, 2019, William Blair & Company, L.L.C., the sole underwriter of the 2019 Offering, exercised its option to purchase additional shares of Aspira common stock for net proceeds of $2,092,000 , after deducting underwriting discounts, commissions and other expenses related to the 2019 Offering.  On April 10, 2020, the Company received a stimulus check of approximately $89,000 from the U.S. Department of Health and Human Services pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the “ CARES Act”) .  As discussed in Note 6, on May 1, 2020, the Company obtained a loan (the “PPP Loan”) from BBVA USA in the aggregate amount of $1,005,767 , pursuant to the Paycheck Protection Program (the “PPP”), which was established under the CARES Act, as administered by the U.S. Small Business Administration (the “SBA”).  As discussed in Note 7, during June 2020, all of the warrants from the 2017 private placement were exercised. The Company received $5,058,608 in aggregate proceeds from the exercise of the warrants.  As discussed in Note 7, on July 20, 2020, the Company completed a private placement of Aspira common stock for net proceeds of $10.6 million, after deducting expenses related to the private placement.  As discussed in Note 12, on February 8, 2021, the Company completed a public offering (the “2021 Offering”), resulting in net proceeds of approximately $48.4 million, after giving effect to the underwriting discounts but before expenses.  As discussed in Note 6, in March 2021, the Company applied for forgiveness of the PPP Loan, but there is no assurance that all or a portion of the PPP Loan will be forgiven.  Basis of Consolidation  The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated in consolidation .   Use of Estimates  The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, income taxes and contingent liabilities. Actual results could differ from those estimates.  Reclassification  Certain prior year amounts have been reclassified to conform to the current year presentation with no material effect on the consolidated financial statements.  Cash and Cash Equivalents  Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes. Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities.  Fair Value Measurement  Accounting Standards Codification (“ASC”) Topic 820, Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:  Level 1 - Quoted prices in active markets for identical assets or liabilities.  Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.  Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.  If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation.  Concentration of Credit Risk  Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000 , but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities.  Accounts Receivable  Virtually all accounts receivable are derived from sales made to customers located in North America. The Company performs ongoing credit evaluations of its customers’ financial condition and generally does not require collateral. The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable.  Property and Equipment  Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations.  Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized.  Revenue Recognition  Product Revenue – OVA1, OVERA and OVA1plus: The Company recognizes product revenue in accordance with the provisions of ASC 606 . Product revenue is recognized upon completion of the OVA1, OVERA or OVA1plus test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year.  The Company also reviews its patient account population and determines an appropriate distribution of patient accounts by payer (i.e., Medicare, patient pay, other third-party payer, etc.) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. During the year ended December 31, 2020, there were no adjustments to estimates of variable consideration to derecognize revenue for services provided in a prior period. There were no impairment losses on accounts receivable recorded during the years ended December 31, 2020 and 2019.  Genetics Revenue – Aspira GenetiX: Under ASC 606, the Company’s genetics revenue is recognized upon completion of the Aspira GenetiX test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the Company has limited experience with such factors relating to Aspira GenetiX.  Service Revenue : The Company’s service revenue was generated by performing IVD trial services for third-party customers. Measurement of progress on contracts with customers was generally based on the input measurement of cost incurred relative to the total expected costs to satisfy the performance obligation. The Company does not expect to have any significant service revenue going forward, as it largely wound down performing the ASPiRA IVD trial services in the fourth quarter of 2019. During 2020, the Company’s service revenue was limited to the fulfillment of one legacy IVD contract. The Company has not disclosed the value of unsatisfied performance obligations for all service revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The remainder are not material to the consolidated financial statements.  Research and Development Costs  Research and development costs are expensed as incurred. Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on behalf of the Company. In addition, acquisitions of assets to be consumed in research and development, with no alternative future use, are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established.  Patent Costs  Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated approximately $322,000 and $203,000 for the years ended December 31, 2020 and 2019, respectively.  Stock-Based Compensation  The Company records the fair value of non-cash stock-based compensation costs for stock options related to the 2019 Stock Incentive Plan (“2019 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. The Company uses the straight-line method to amortize the fair value over the requisite service period of the award, which is generally equal to the vesting period. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment.  The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding. This data includes employees’ expected exercise and post-vesting employment termination behaviors. The expected stock price volatility is estimated using Company historical volatility in deriving the expected volatility assumption . The Company made an assessment that Company historic volatility is most representative of future stock price trends. The expected dividend yield is based on the estimated annual dividends that are expected to be paid over the expected life of the options as a percentage of the market value of the Company’s common stock as of the grant date. The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date. The Company records stock-based compensation net of estimated forfeitures.  Contingencies  The Company accounts for contingencies in accordance with ASC 450 Contingencies (“ASC 450”) which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Management believes that the Company’s accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates.  Income Taxes  The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized.  ASC Topic 740, Accounting for Uncertainty in Income Taxes clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure.  The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets.  Net Loss Per Share  Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period. Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share.  Fair Value of Financial Instruments  Financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments. The carrying value of debt approximates fair value due to its interest rate approximating market rates of interest available to the Company for similar instruments.  Segment Reporting  The Company’s chief operating decision maker evaluates the business on a consolidated basis and therefore, the Company operates one operating and reportable segment. 

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2020
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	NOTE 2: Recent Accounting Pronouncements  In June 201 6 , the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . This update changes the impairment model from the currently used incurred loss methodology to an expected loss methodology, which will result in the more timely recognition of losses. The ASU is scheduled to be effective in 2023 for smaller reporting companies. The Company is currently assessing the impact of this ASU on its consolidated financial statements . 

Strategic Alliance With Quest D

Strategic Alliance With Quest Diagnostics Incorporated	12 Months Ended
	Dec. 31, 2020
Strategic Alliance With Quest Diagnostics Incorporated [Abstract]
Strategic Alliance With Quest Diagnostics Incorporated	NOTE 3: Strategic Alliance with Quest Diagnostics Incorporated  In March 201 5, the Company reached an agreement with Quest Diagnostics, Incorporated (“Quest Diagnostics”). Pursuant to this agreement, all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Aspira’s wholly-owned subsidiary, ASPiRA LABS, as of August 201 5. Pursuant to this agreement, as amended as of March 11, 2020, Quest Diagnostics has continued to provide blood draw and logistics support by transporting specimens to ASPiRA LABS for testing in exchange for a market value fee. The purpose of the 2020 a mendment was to extend the term of the Testing and Services Agreement from March 11, 2019 to March 11, 2023 and for the Company to pay an annual fee of $75,000 for the services of a part-time Quest Diagnostics project manager. 

Property And Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2020
Property And Equipment [Abstract]
Property And Equipment	Note 4: Property and Equipment  The components of property and equipment as of December 31, 2020 and 2019 were as follows :      December 31,  (in thousands) 2020 2019  Machinery and equipment $ 1,094 $ 841  Demonstration equipment 17 16  Computer equipment and software 1,194 1,094  Furniture and fixtures 154 144  Leasehold improvements 701 639  Gross property and equipment 3,160 2,734  Accumulated depreciation and amortization (2,577) (2,381)  Property and equipment, net $ 583 $ 353  Depreciation expense for property and equipment was $265,000 and $333,000 for the years ended December 31, 2020 and 2019, respectively.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2020
Accrued Liabilities [Abstract]
Accrued Liabilities	NOTE 5: Accrued Liabilities  The components of accrued liabilities as of December 31, 2020 and 2019 were as follows:      December 31,  (in thousands) 2020 2019  Payroll and benefits related expenses $ 1,874 $ 1,229  Collaboration and research agreements expenses 616 350  Professional services 803 679  Other accrued liabilities 325 330  Total accrued liabilities $ 3,618 $ 2,588 

Commitments, Contingencies And

Commitments, Contingencies And Debt	12 Months Ended
	Dec. 31, 2020
Commitments, Contingencies And Debt [Abstract]
Commitments, Contingencies And Debt	NOTE 6: Commitments, Contingencies and debt  Long-term debt consisted of the following:   Year Ended  December 31,  2020 2019  (in thousands)  DECD loan $ 3,070 $ 1,292  PPP loan 1,006 -  Total debt 4,076 1,292  Less: Current portion (999) (193)  Total long-term debt 3,077 1,099  Coronavirus Aid, Relief, and Economic Security (CARES) Act and Paycheck Protection Program Loan  On May 1, 2020, the Company obtained the PPP Loan from BBVA USA in the aggregate amount of $1,005,767 . The application for these funds required the Company to, in good faith, certify that the described economic uncertainty at the time made the loan request necessary to support the ongoing operations of the Company. This certification further required the Company to consider its current business activity and its ability to access other sources of liquidity sufficient to support ongoing operations in a manner that was not significantly detrimental to the business. Under the terms of the CARES Act and the PPP, all or a portion of the principal amount of the PPP Loan is subject to forgiveness so long as, over the 24-week period following the Company’s receipt of the proceeds of the PPP Loan, the Company use s those proceeds for payroll costs, rent, utility costs or the maintenance of employee and compensation levels. The PPP Loan, which was granted pursuant to a promissory note, matures on May 1, 2022. Any unforgiven portion of the PPP Loan bears interest at a rate of 1.000% per annum, payable monthly in equal installments commencing in May 2021. The Company applied for forgiveness of the PPP Loan in March 2021, but there is no assurance that all or a portion of the PPP Loan will be forgiven. Th e PPP Loan is subject to any new guidance and new requirements released by the Department of the Treasury.  Loan Agreement  On March 22, 2016, the Company entered into a loan agreement (as amended, the “Loan Agreement”) with the DECD, pursuant to which the Company may borrow up to $4,000,000 from the DECD. The loan bears interest at a fixed rate of 2.0% per annum and requires equal monthly payments of principal and interest until maturity, which occurs on April 15, 2026 . As security for the loan, the Company has granted the DECD a blanket security interest in the Company’s personal and intellectual property. The DECD’s security interest in the Company’s intellectual property may be subordinated to a qualified institutional lender.  The loan may be prepaid at any time without premium or penalty. An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. On December 3, 2020, the Company received a disbursement of the remaining $2,000,000 under the Loan Agreement, as the Company had achieved the target employment milestone necessary to receive an additional $1,000,000 under the Loan Agreement and the DECD determined to fund the remaining $1,000,000 under the Loan Agreement after concluding that the required revenue target would likely have been achieved in the first quarter of 2020 in the absence of the impacts of COVID-19.  Under the terms of the Loan Agreement, the Company may be eligible for forgiveness of up to $1,500,000 of the principal amount of the loan if the Company achieves certain job creation and retention milestones by December 31, 2022. Conversely, if the Company is either unable to retain 25 full-time employees with a specified average annual salary for a consecutive two -year period or does not maintain the Company’s Connecticut operations through March 22, 2026, the DECD may require early repayment of a portion or all of the loan plus a penalty of 5% of the total funded loan.  As of December 31, 2020, the annual amounts of future minimum principal payments due under certain of the Company’s contractual obligations are shown in the table below. Debt issuance costs for the DECD loan were $18,000 . Debt related to the PPP L oan of $1,000,000 and that certain insurance promissory note of $611,000 , as described below, are not included in the table below, as the PPP L oan is expected to be forgiven and the $6 11 ,000 insurance promissory note is cancelable.     Payments Due by Period  (in thousands) Total 2021 2022 2023 2024 2025 Thereafter  DECD Loan 3,088 508 564 576 588 599 253  Total $ 3,088 $ 508 $ 564 $ 576 $ 588 $ 599 $ 253  Insurance Notes  During 2020 and 2019, the Company entered into insurance promissory notes for the payment of insurance premiums at an interest rate of 3.88% and 4.49% respectively, with an aggregate principal amount outstanding of approximately $611,000 and $303,000 as of December 31, 2020 and 2019, respectively. The amount outstanding could be substantially offset by the cancellation of the related insurance coverage which is classified in prepaid insurance. These notes are payable in ten monthly installments with maturity dates of October 1, 2021 and October 1, 2020, respectively.  Operating Leases  The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease. The Company’s principal facility, including the CLIA laboratory used by ASPiRA LABS, is located in Austin, Texas, and the CLIA laboratory used for ASPiRA IVD services is located in Trumbull, Connecticut. In October 2020, the Company renewed the Austin, Texas lease for one additional year. The Company’s renewed lease expires on January 31, 2022, with no automatic renewal or renewal option.  In October 2015, the Company entered into a lease agreement for a facility in Trumbull, Connecticut. The lease required initial payments for the buildout of leasehold improvements to the office space, which were approximately $596,000 . In September 2020, the Company exercised the renewal option for its Trumbull, Connecticut lease. The Company’s renewed lease expires on June 30, 2026 , with a five year renewal option. The Company is not reasonably certain that it will exercise the five year renewal option beginning on July 1, 2026.  The expense associated with these operating leases for the years ended December 31, 2020 and 2019 is shown in the table below (in thousands ).      Year Ended December 31  Lease Cost Classification 2020 2019  Operating rent expense  Cost of revenue $ 71 $ 38  Research and development 50 11  Sales and marketing 29 35  General and administrative 66 46  Variable rent expense  Cost of revenue $ 7 $ 49  Research and development 1 14  Sales and marketing 45 41  General and administrative 54 57  Based on our leases as of December 31, 2020, the table below sets forth the approximate future lease payments related to operating leases with initial terms of one year or more (in thousands ).     2021 $ 63  2022 95  2023 106  2024 116  2025 123  2026 64  Total Operating Lease Payments 567  Less: Interest (135)  Present Value of Lease Liabilities $ 432   Weighted-average lease term and discount rate were as follows:   Weighted-average remaining lease term (in years) 5.5  Weighted-average discount rate 9.38%  Non-cancelable Collaboration Obligations and Other Commitments  The Company is a party to an amended research collaboration agreement with The Johns Hopkins University School of Medicine under which the Company licenses certain of its intellectual property directed at the discovery and validation of biomarkers in human subjects, including but not limited to clinical application of biomarkers in the understanding, diagnosis and management of human diseas e. Under the terms of the amended research collaboration agreement, Aspira is required to pay the greater of 4% royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of $57,500 . Royalty expense for the years ended December 31, 2020 and 2019 totaled $181,000 and $176,000 , respectively.  Contingent Liabilities  From time to time, the Company is involved in legal proceedings and regulatory proceedings arising from operations. The Company establishes reserves for specific liabilities in connection with legal actions that management deems to be probable and estimable. The Company is not currently a party to any proceeding, the adverse outcome of which would have a material adverse effect on the Company’s financial position or results of operations.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2020
Common Stock [Abstract]
Common Stock	NOTE 7: Common Stock  2019 Offering  On June 26, 2019, the Company entered into an underwriting agreement (the “2019 Underwriting Agreement”) with William Blair & Company, L.L.C., as the sole underwriter (the “2019 Underwriter”), in connection with the underwritten public offering of 18,750,000 shares of the Company’s common stock , par value $0.001 per share .  Pursuant to the 2019 Underwriting Agreement, the Company agreed to issue and sell an aggregate of 18,750,000 shares of Aspira common stock offered by the 2019 Underwriter in a public offering at a price of $0.80 per share (the “2019 Offering”). The 2019 Offering closed on June 28, 2019 and resulted in net proceeds to the Company of approximately $13,521,000 , after deducting expenses of approximately $1,500,000 .  Under the 2019 Underwriting Agreement, the Company granted the 2019 Underwriter an option to purchase up to an additional 2,812,500 shares of Aspira common stock at the public offering price, less underwriting discounts and commissions. On July 2, 2019, the 2019 Underwriter exercised its option to purchase 2,812,500 shares of Aspira common stock at a price of $0.80 per share and resulted in proceeds to the Company of approximately $2,092,000 , after deducting underwriting discounts, commissions and other expenses related to the offering .  2020 Exercise of Warrants  On February 17, 2017, the Company issued certain warrants to purchase up to an aggregate of 2,810,338 shares of Aspira common stock at an exercise price of $1.80 per share in connection with a February 2017 private placement of Aspira common stock. The warrants were initially sold at a price of $0.125 per share of common stock underlying the warrants .  On June 1, 2020, following the 20th consecutive trading day for which the closing price per share of Aspira common stock, as reported on the Nasdaq stock market, exceeded the exercise price, the Company sent notice to the investors holding such warrants accelerating the expiration date of the warrants, in accordance with the terms thereof. Pursuant to the terms of the warrants, any portion of the warrants not exercised prior to such accelerated expiration date would become void and of no value.  As of June 9, 2020, all of the warrants were exercised. The Company issued 2,810,338 shares of Aspira common stock and received $5,060,000 in aggregate proceeds from the exercise of the warrants. As of the date of the issuance of these financial statements, there are no outstanding warrants for the purchase of Aspira common stock .  2020 Private Placement  On July 20, 2020, the Company completed a private placement pursuant to which certain investors purchased 3,150,000 shares of Aspira common stock at a price of $3.50 per share. Net proceeds of the private placement were $10.6 million, after deducting expenses related to the private placement of $384,000 . The sale of common stock qualified for equity treatment under GAAP.  

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2020
Loss Per Share [Abstract]
Loss Per Share	NOTE 8: Loss Per Share  The reconciliation of the numerators and denominators of basic and diluted loss per share for the years ended December 31, 2020 and 2019 was as follows:     Loss Shares Per Share  (In thousands, except shares and per share data) (Numerator) (Denominator) Amount  Year ended December 31, 2019:  Net loss available to common shareholders - basic $ (15,237) 86,595,581 $ (0.18)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss available to common shareholders - diluted $ (15,237) 86,595,581 $ (0.18)   Year ended December 31, 2020:  Net loss available to common shareholders - basic $ (17,905) 100,723,303 $ (0.18)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss available to common shareholders - diluted $ (17,905) 100,723,303 $ (0.18)  Due to net losses for the years ended December 31, 2020 and 2019, diluted loss per share is calculated using the weighted average number of common shares outstanding and excludes the effects of potential shares of common stock that are antidilutive.  The potential shares of common stock that have been excluded from the diluted loss per share calculation above for the years ended December 31, 2020 and 2019 were as follows:      Year Ended December 31,  2020 2019  Stock options 8,212,112 6,612,878  Stock warrants - 2,810,338  Unvested restricted stock awards - -  Potential common shares 8,212,112 9,423,216 

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2020
Employee Benefit Plans [Abstract]
Employee Benefit Plans	NOTE 9: Employee Benefit Plans  2010 Stock Incentive Plan  The Company’s employees, directors, and consultants were eligible to receive awards under the Vermillion, Inc. Second Amended and Restated 2010 Stock Incentive Plan, which was replaced by the 2019 Plan (as defined below) with respect to future equity grants. As of December 31, 2020, a total of 4,776,503 shares of Aspira common stock were reserved for issuance with respect to outstanding stock options.  2019 Stock Incentive Plan  At the Company’s 2019 annual meeting of stockholders, the Company’s stockholders approved the Vermillion, Inc. 2019 Stock Incentive Plan (the “2019 Plan”). The purposes of the 2019 Plan are (i) to align the interests of the Company’s stockholders and recipients of awards under the 2019 Plan by increasing the proprietary int erest of such recipients in the Company’s growth and success; (ii) to advance the interests of the Company by attracting and retaining non-employee directors, officers, other employees, consultants, independent contractors and agents; and (iii) to motivate such persons to act in the long-term best interests of the Company and its stockholders. The 2019 Plan allows the Company to grant stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to participants.  Subject to the terms and conditions of the 2019 Plan, the initial number of shares authorized for grants under the 2019 Plan is 10,492,283 . To the extent an equity award granted under the 2019 Plan expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares of common stock subject to such award will become available for future grant under the 2019 Plan. As of December 31, 2020, there were 10,492,283 shares of Aspira common stock available for future grants under the 2019 Plan. As of December 31, 2020, there were 3,442,109 shares of Aspira common stock subject to outstanding stock options and there were no outstanding restricted stock units .  The activity related to shares available for grant under the 2010 Plan and the 2019 Plan for the years ended December 31, 2020 and 2019 was as follows:      2010 Stock Option Plan 2019 Stock Option Plan Total  Shares available at December 31, 2018 5,178,819 - 5,178,819  Shares added - 8,000,000 8,000,000  Shares transferred (2,492,283) 2,492,283 -  Options canceled 691,025 - 691,025  Options granted (2,504,585) (207,000) (2,711,585)  Restricted stock units granted (202,576) - (202,576)  Shares available at December 31, 2019 670,400 10,285,283 10,955,683   Options canceled 718,500 502,000 1,220,500  Options granted - (3,925,409) (3,925,409)  Restricted stock units granted - (356,940) (356,940)  Shares forfeited (1,388,900) - (1,388,900)  Shares available at December 31, 2020 - 6,504,934 6,504,934  The stock option activity under the 2010 Plan and the 2019 Plan for the years ended December 31, 2020 and 2019 was as follows:     Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term  Options outstanding at December 31, 2018 4,612,005 $ 1.67 $ - 7.17  Granted 2,711,585 1.02  Exercised (19,687) 1.32  Canceled (691,025) 1.79  Options outstanding at December 31, 2019 6,612,878 $ 1.67 $ 303,995 8.66  Granted 3,925,409 1.46  Exercised (1,105,675) 1.48  Canceled (1,220,500) 0.75  Options outstanding at December 31, 2020 8,212,112 $ 1.49 $ 42,833,712 7.51   Shares exercisable:  December 31, 2020 3,743,698 $ 1.56 $ 19,272,201 6.41  Shares expected to vest:  December 31, 2020 4,468,414 $ 1.44 $ 23,561,533 8.91  The range of exercise prices for options outstanding and exercisable at December 31, 2020 is as follows:      Exercise Price Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Life in Years Options Exercisable Weighted Average Exercise Price  $ 0.47 - $ 0.68 2,157,468 $ 0.64 8.59 613,968 $ 0.61  0.71 - 1.29 3,012,383 1.11 7.93 1,039,133 1.18  1.31 - 2.83 2,102,197 1.87 5.64 1,750,572 1.80  2.87 - 4.80 940,064 3.88 7.84 340,025 3.23   $ 0.47 - $ 4.80 8,212,112 $ 1.49 7.51 3,743,698 $ 1.56       (in thousands) Total Intrinsic Value of Options Exercised Total Fair Value of Vested Options  Year ended December 31, 2020 $ 3,439 $ 3,254  Year ended December 31, 2019 $ 8 $ 2,869  Stock-based Compensation  Stock-based Compensation Expense  The Company records stock-based compensation net of estimated forfeitures. The assumptions used to calculate the fair value of options granted under the 2010 Plan and the 2019 Plan that were incorporated in the Black-Scholes pricing model for the years ended December 31, 2020 and 2019 were as follows:       Year Ended December 31,  2020 2019  Dividend yield - % - %  Volatility 84 % 79 %  Risk-free interest rate 0.71 % 2.30 %  Expected lives (years) 2.9 4.0  Weighted average grant date fair value $ 0.87 $ 0.55  The allocation of employee and director stock-based compensation expense by functional area for the years ended December 31, 2020 and 2019 was as follows:      Year Ended December 31,  (in thousands) 2020 2019  Cost of sales $ 96 $ 67  Research and development 33 4  Sales and marketing 162 122  General and administrative 924 942  Total $ 1,215 $ 1,135  As of December 31, 2020, total unrecognized compensation cost related to unvested stock option awards was approximately $2,970,000 and the related weighted average period over which it is expected to be recognized was 2.72 years. As of December 31, 2020, there was no unrecognized compensation costs related to restricted stock units.  401(k) Plan  The Company’s 401(k) Plan allows eligible employees to defer up to an annual limit of the lesser of 90.0% of eligible compensation or a maximum contribution amount subject to the Internal Revenue Service annual contribution limit. The Company is not required to make Company contributions under the 401(k) Plan. During the years ended December 31, 2020 and 2019, the Company did no t make Company contribut ions to the 401(k) Plan.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Taxes [Abstract]
Income Taxes	NOTE 10: Income Taxes  During the preparation of the 2020 financial statements, immaterial errors were identified in the Company’s previous deferred tax disclosures. The Company has determined that a revision was required to correct certain gross deferred tax assets to reflect the proper amount of federal net operating loss carryforwards, to properly include state income taxes, and to properly exclude uncertain tax credit carryforwards. Specifically , portions of the net operating losses (“ NOLs ”) that are subject to S ection 382 of the Internal Revenue Code of 1986, as amended (“Section 382”) limitations , but were not limited, were excluded from deferred tax assets which led to an understatement of the deferred tax asset by $5,535,246 (tax effected); deferred state income taxes were not recorded, which led to an understatement of deferred tax assets of $2,466,759 (tax effected); and tax credit carryovers were incorrectly reflected, which led to an overstatement of deferred tax assets of $10,643,355 (tax effected). The net impact was an overstatement of deferred tax assets of $2,641,350 . However, there was no net impact to the net deferred tax asset and tax expense as the change in deferred tax assets was offset completely by a corresponding adjustment to the Company’s valuation allowance. For comparative purposes, the Company’s 2019 tax disclosure has been revised to reflect the adjustment to the deferred tax assets and valuation allowance. The Company evaluated the errors and concluded the impact was not material. The effect of these revisions to the net deferred tax asset balance was zero, and the revision had no impact on the Company’s consolidated balance sheet, statement of operations or statement of cash flows .  There was no income tax expense or benefit for the years ended December 31, 20 20 or 201 9 because of net losses during those years. These net losses were generated from domestic operations.  Domestic and foreign components of loss from continuing operations before income taxes for the years ended December 31, 2020 and 2019 were $17,905,000 and $15,236,000 , respectively.   Based on the available objective evidence, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets at December 31, 2020 and 2019. There was no income tax expense or benefit for the years ended December 31, 2020 or 2019 .  The components of net deferred tax assets (liabilities) at December 31, 20 20 and 20 19 were as follows:       Year Ended December 31,  (in thousands) 2020 2019  Deferred tax assets:  Net operating losses $ 32,740 $ 28,939  Amortization - R&D intangibles 2,495 2,810  Other - 124  Total deferred tax assets 35,235 31,873  Valuation allowance (35,195) (31,873)  Deferred tax assets $ 40 $ -   Deferred tax liabilities:  Other $ 40 $ -  Deferred tax liabilities $ 40 $ -   Net deferred tax asset $ - $ -  The reconciliation of the statutory federal income tax rate to the Company’s effective tax rate for the years ended December 31, 20 20 and 201 9 was as follows:       Year Ended December 31,  2020 2019  Tax at federal statutory rate 21 % 21 %  State tax, net of federal benefit 1 1  Valuation allowance (19) (42)  Net operating loss and tax credit carryforwards (2) 23  Permanent items (1) (1)  Other - (2)  Effective income tax rate - % - %  As a result of the Tax Cuts and Jobs Act of 2017, federal NOLs arising before January 1, 2018, and federal NOLs arising after January 1, 2018, are subject to different rules. The Company's pre- 2018 federal NOLs will expire in varying amounts from 2021 through 2037, if not utilized; and can offset 100% of future taxable income for regular tax purposes. Any federal NOLs arising after January 1, 2018, can generally be carried forward indefinitely and can offset up to 80% of future taxable income. State NOLs will expire in varying amounts from 2021 through 2037 if not utilized. The Company's ability to use its NOLs during this period will be dependent on the Company's ability to generate taxable income, and the NOLs could expire before the Company generates sufficient taxable income .  The Company's ability to use its net operating loss and credit carryforwards may be restricted due to ownership change limitations occurring in the past or that could occur in the future, as required by Section 382, as well as similar state provisions. These ownership changes may also limit the amount of net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively .  The Company believes that Section 382 ownership changes occurred as a result of the Company's follow-on public offerings in 2011, 2013, and 2015. Any limitation may result in the expiration of a portion of the net operating loss and tax credit carryforwards before utilization and any net operating loss and tax credit carryforwards that expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the Company's valuation allowance. Due to the existence of a valuation allowance, it is not expected that such limitations, if any, will have an impact on the Company's results of operations or financial position .  Provisional amounts  Company management believe s that it is more likely than not that the benefit from certain deferred tax assets will not be realized due to the history of our operating losses. In recognition of this risk, the Company has provided a valuation allowance on the deferred tax assets relating to these assets . The valuation allowance was approximately $ 35,200 ,000 and $ 31,900 ,000 at December 31, 20 20 and 201 9 , respectively. The increase of approximately $3,300,000 between 2019 and 2020 is primarily due to adjustments to the domestic deferred tax assets related to net operating losses .  The Company files income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. The Company has not been audited by the Internal Revenue Service or any state income or franchise tax agency. As of December 31, 2020, the Company's federal returns for the years ended 2017 through the current period and most state returns for the years ended 2016 through the current period are still open to examination. In addition, all of the net operating losses and research and development credits generated in years earlier than 2017 and 2016, respectively, are still subject to Internal Revenue Service audit. The federal and California tax returns for the year ended December 31, 2019 reflect research and development carryforwards of $5,292,000 and $5,351,000 , respectively. For the year ended December 31, 2020, the Company anticipates claiming additional research and development credits of $20,000 on its federal tax return and $45,000 on its California tax return.  As of December 31, 2020, the Company's gross unrecognized tax benefits are approximately $10,517,000 which are attributable to research and development credits. A reconciliation of the change in the Company's unrecognized tax benefits is as follows :       (in thousands) Federal Tax State Tax Total  Balance at December 31, 2018 $ 5,637 $ 5,330 $ 10,967  Return to provision true up (210) - (210)  Increase in tax position during 2019 - 21 21  Decrease due to expirations during 2019 (134) - (134)  Balance at December 31, 2019 $ 5,293 $ 5,351 $ 10,644  Return to provision true up - - -  Increase in tax position during 2020 20 45 65  Decrease due to expirations during 2020 (192) - (192)  Balance at December 31, 2020 $ 5,121 $ 5,396 $ 10,517  The increase for the year ended December 31, 2020 relates to a position taken in the current year. The increase for the year ended December 31, 2019 is related to tax positions taken during 2019 and prior years. If the $10.5 million of unrecognized income tax benefit is recognized, approximately $10.5 million would impact the effective tax rate in the period in which each of the benefits is recognized .  The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the consolidated statement of operations and comprehensive loss. The Company has no t recorded any interest or penalties as a result of uncertain tax positions as of December 31, 2020 and 2019. Accrued interest and penalties would be included within the related liability in the consolidated balance sheet .

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 11: Related Party Transactions  None.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 12: SUBSEQUENT EVENTS  On February 4, 2021, the Company entered into an underwriting agreement (the “2021 Underwriting Agreement”) with William Blair & Company, L.L.C. and Truist Securities, Inc., as representatives of several underwriters (the “2021 Underwriters”), in connection with the underwritten public offering of 6,000,000 shares of the Company’s common stock , par value $0.001 per share (the “2021 Firm Shares”) , at a price to the public of $7.50 per share. The 2021 Underwriters purchased the 2021 Firm Shares at the public offering price per share, less the underwriting discount of $0.4875 per share.  Under the 2021 Underwriting Agreement, the Company granted the 2021 Underwriters an option to purchase up to an additional 900,000 shares of Aspira common stock , par value $0.001 per share (the “2021 Option Shares”) , at the public offering price, less the underwriting discount of $0.4875 per share. On February 5, 2021, the 2021 Underwriters notified the Company that they were exercising this option in connection with the closing of the 2021 Offering. The 2021 Offering, including the 2021 Option Shares, closed on February 8, 2021 and resulted in net proceeds to the Company of approximately $48.4 million , after giving effect to underwriting discounts but before expenses. 

Basis Of Presentation And Sum_2

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Policy)	12 Months Ended
	Dec. 31, 2020
Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation  Aspira Women’s Health Inc., formerly known as Vermillion, Inc. (“Aspira” and its wholly-owned subsidiaries are collectively referred to as the “Company ” ) is incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company currently markets and sells the following products and related services: (1) OVA1, a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at high - risk of having a malignant ovarian tumor prior to planned surgery; (2) OVERA, a second-generation biomarker panel intended to maintain our product’s high sensitivity while improving specificity; (3) OVA1plus, a service offering combining our OVA1 and OVERA products, designed to improve accuracy and reduce false elevations in the intermediate risk area by leveraging the strengths of OVA1’s (MIA) sensitivity and OVERA’s (MIA2G) specificity; (4) Aspira GenetiX, a genetic test for gynecologic cancer risk, with a core focus on female reproductive cancers, including breast, ovarian, endometrial, uterine and cervical cancers ; and (5) Aspira Synergy, the Company’s new decentralized platform and cloud service technology. T hrough December 31, 2020, the Company’s product and related services revenue was limited to revenue generated by sales of OVA1, OVA1plus and Aspira GenetiX . The Company sells OVA1 and OVA1plus through Aspira’s wholly-owned Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) certified clinical laboratory, Aspira Labs, Inc. (“ASPiRA LABS”).  The Company has historically also offered in-vitro diagnostic (“IVD”) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (“ASPiRA IVD”), which commenced operations in June 2016. ASPiRA IVD was a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize high-complexity assays. The Company has discontinued pursuing contracts for ASPiRA IVD and its contractual commitments were largely concluded in the fourth quarter of 2019 .  Effective January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-02, Leases (“ASU 2016-02”), and elected the package of practical expedients, including the hindsight practical expedient and the new transition approach permitted by ASU No. 2018-11, Leases, Targeted Improvements (“ASU 2018-11”). The standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2018-11 allows the Company not to reassess existing identification of leases, classification of leases or any initial direct costs. The Company has two office leases, one of which has as lease less than 12 months. The Company recognized ROU assets and a lease liability of approximately $178,000 related to its leases on its consolidated balance sheet as of January 1, 2019. The Company did no t have a cumulative adjustment impacting retained earnings.  Effective January 1, 2020, the Company adopted FASB ASU No. 2018-15, Intangibles-Goodwill and Other-Internal Use Software: Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , using the prospective transition approach, which allows the Company to change the accounting method without restating prior periods or booking cumulative adjustments . ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The adoption of ASU 2018-15 did not have a material impact on the consolidated financial statements. 
Liquidity	Liquidity  The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximately $440,066,000 and had limited liquidity at December 31, 2020. The Company also expects to incur a net loss and negative cash flows from operations for 2021.  In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China. The novel coronavirus has since spread to over 100 countries, including every state in the United States. In March 2020, the World Health Organization declared COVID-19, the disease caused by the novel coronavirus, a pandemic, and the United States declared a national emergency with respect to the coronavirus outbreak. This outbreak has severely impacted global economic activity, and many countries and many states in the United States have reacted to the outbreak by instituting quarantines, mandating business and school closures and restricting travel. In addition, many conventions and industry conferences have been canceled.  As a result of the COVID-19 pandemic and actions taken to contain it, the Company’s test volume, and resulting revenue, decreased significantly in late March and the full month of April 2020 as fewer patients visited their physicians and elective surgeries were postponed as a result of closures. The Company saw some increases in its test volume towards the latter half of the second quarter and in the third quarter of 2020, and test volume trended back to pre-COVID-19 levels during the late third quarter 2020. In order to reduce the impact of limitations on visiting physician offices due to closures and quarantines, the Company implemented other mechanisms for reaching physicians such as virtual sales representative meetings and increased digital sales and marketing. E nrollment for future studies has been slower than originally planned due to the impact of current closures for some states. The full impact of the COVID-19 pandemic continues to evolve as of the date of this filing. As a result, the Company is unable to estimate the extent of the impact of the COVID-19 pandemic on its liquidity.  As discussed in Note 6, in March 2016, the Company entered into a loan agreement (as amended on March 7, 2018 and April 3, 2020, the “Loan Agreement”) with the State of Connecticut Department of Economic and Community Development (the “DECD”), pursuant to which it may borrow up to $4,000,000 from the DECD.  The loan may be prepaid at any time without premium or penalty. An initial disbursement of $2,000,000 was made to the Company on April 15, 2016 under the Loan Agreement. On December 3, 2020, the Company received a disbursement of the remaining $2,000,000 under the Loan Agreement, as the Company had we achieved the target employment milestone necessary to receive an additional $1,000,000 under the Loan Agreement and the DECD determined to fund the remaining $1,000,000 under the Loan Agreement after concluding that the required revenue target would likely have been achieved in the first quarter of 2020 in the absence of the impacts of COVID-19.  As discussed in Note 7, on June 28, 2019, the Company completed a public offering (the “2019 Offering”), pursuant to which certain investors purchased Aspira common stock for net proceeds of approximately $13,521,000 after deducting underwriting discounts, commissions and other expenses related to the 2019 Offering. On July 2, 2019, William Blair & Company, L.L.C., the sole underwriter of the 2019 Offering, exercised its option to purchase additional shares of Aspira common stock for net proceeds of $2,092,000 , after deducting underwriting discounts, commissions and other expenses related to the 2019 Offering.  On April 10, 2020, the Company received a stimulus check of approximately $89,000 from the U.S. Department of Health and Human Services pursuant to the Coronavirus Aid, Relief, and Economic Security Act (the “ CARES Act”) .  As discussed in Note 6, on May 1, 2020, the Company obtained a loan (the “PPP Loan”) from BBVA USA in the aggregate amount of $1,005,767 , pursuant to the Paycheck Protection Program (the “PPP”), which was established under the CARES Act, as administered by the U.S. Small Business Administration (the “SBA”).  As discussed in Note 7, during June 2020, all of the warrants from the 2017 private placement were exercised. The Company received $5,058,608 in aggregate proceeds from the exercise of the warrants.  As discussed in Note 7, on July 20, 2020, the Company completed a private placement of Aspira common stock for net proceeds of $10.6 million, after deducting expenses related to the private placement.  As discussed in Note 12, on February 8, 2021, the Company completed a public offering (the “2021 Offering”), resulting in net proceeds of approximately $48.4 million, after giving effect to the underwriting discounts but before expenses.  As discussed in Note 6, in March 2021, the Company applied for forgiveness of the PPP Loan, but there is no assurance that all or a portion of the PPP Loan will be forgiven. 
Basis Of Consolidation	Basis of Consolidation  The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated in consolidation
Use Of Estimates	Use of Estimates  The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The primary estimates underlying the Company’s consolidated financial statements include assumptions regarding revenue recognition as well as variables used in calculating the fair value of the Company’s equity awards, income taxes and contingent liabilities. Actual results could differ from those estimates. 
Reclassification	Reclassification  Certain prior year amounts have been reclassified to conform to the current year presentation with no material effect on the consolidated financial statements. 
Cash And Cash Equivalents	Cash and Cash Equivalents  Cash and cash equivalents consist of cash and highly liquid investments with maturities of three months or less from the date of purchase, which are readily convertible into known amounts of cash and are so near to their maturity that they present an insignificant risk of changes in value because of interest rate changes. Highly liquid investments that are considered cash equivalents include money market funds, certificates of deposits, treasury bills and commercial paper. The carrying value of cash equivalents approximates fair value due to the short-term maturity of these securities. 
Fair Value Measurement	Fair Value Measurement  Accounting Standards Codification (“ASC”) Topic 820, Fair Value and Measurements (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:  Level 1 - Quoted prices in active markets for identical assets or liabilities.  Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.  Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.  If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation.
Concentration Of Credit Risk	Concentration of Credit Risk  Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company maintains cash and cash equivalents in recognized financial institutions in the United States. The funds are insured by the FDIC up to a maximum of $250,000 , but are otherwise unprotected. The Company has not experienced any losses associated with deposits of cash and cash equivalents. The Company does not invest in derivative instruments or engage in hedging activities. 
Accounts Receivable	Accounts Receivable  Virtually all accounts receivable are derived from sales made to customers located in North America. The Company performs ongoing credit evaluations of its customers’ financial condition and generally does not require collateral. The Company maintains an allowance for doubtful accounts based upon the expected collectability of accounts receivable. 
Property And Equipment	Property and Equipment  Property and equipment are carried at cost less accumulated depreciation and amortization. Property and equipment are depreciated when placed into service using the straight-line method over the estimated useful lives, generally three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations.  Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If property and equipment are considered to be impaired, an impairment loss is recognized. 
Revenue Recognition	Revenue Recognition  Product Revenue – OVA1, OVERA and OVA1plus: The Company recognizes product revenue in accordance with the provisions of ASC 606 . Product revenue is recognized upon completion of the OVA1, OVERA or OVA1plus test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the collection cycle on some accounts can be as long as one year.  The Company also reviews its patient account population and determines an appropriate distribution of patient accounts by payer (i.e., Medicare, patient pay, other third-party payer, etc.) into portfolios with similar collection experience. The Company has elected this practical expedient that, when evaluated for collectability, results in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on an individual contract basis. During the year ended December 31, 2020, there were no adjustments to estimates of variable consideration to derecognize revenue for services provided in a prior period. There were no impairment losses on accounts receivable recorded during the years ended December 31, 2020 and 2019.  Genetics Revenue – Aspira GenetiX: Under ASC 606, the Company’s genetics revenue is recognized upon completion of the Aspira GenetiX test and delivery of results to the physician based on estimates of amounts that will ultimately be realized. In determining the amount of revenue to be recognized for a delivered test result, the Company considers factors such as payment history and amount, payer coverage, whether there is a reimbursement contract between the payer and the Company, and any developments or changes that could impact reimbursement. These estimates require significant judgment by management as the Company has limited experience with such factors relating to Aspira GenetiX.  Service Revenue : The Company’s service revenue was generated by performing IVD trial services for third-party customers. Measurement of progress on contracts with customers was generally based on the input measurement of cost incurred relative to the total expected costs to satisfy the performance obligation. The Company does not expect to have any significant service revenue going forward, as it largely wound down performing the ASPiRA IVD trial services in the fourth quarter of 2019. During 2020, the Company’s service revenue was limited to the fulfillment of one legacy IVD contract. The Company has not disclosed the value of unsatisfied performance obligations for all service revenue contracts with an original expected length of one year or less, which is an optional exemption that is permitted under the adoption rules. The remainder are not material to the consolidated financial statements. 
Research And Development Costs	Research and Development Costs  Research and development costs are expensed as incurred. Research and development costs consist primarily of payroll and related costs, materials and supplies used in the development of new products, and fees paid to third parties that conduct certain research and development activities on behalf of the Company. In addition, acquisitions of assets to be consumed in research and development, with no alternative future use, are expensed as incurred as research and development costs. Software development costs incurred in the research and development of new products are expensed as incurred until technological feasibility is established. 
Patent Costs	Patent Costs  Costs incurred in filing, prosecuting and maintaining patents (principally legal fees) are expensed as incurred and recorded within general and administrative expenses on the Consolidated Statements of Operations. Such costs aggregated approximately $322,000 and $203,000 for the years ended December 31, 2020 and 2019, respectively. 
Stock-Based Compensation	Stock-Based Compensation  The Company records the fair value of non-cash stock-based compensation costs for stock options related to the 2019 Stock Incentive Plan (“2019 Plan”). The Company estimates the fair value of stock options using a Black-Scholes option valuation model. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. The Company uses the straight-line method to amortize the fair value over the requisite service period of the award, which is generally equal to the vesting period. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore are subject to management's judgment.  The expected life of options is based on historical data of actual experience with the options granted and represents the period of time that the options granted are expected to be outstanding. This data includes employees’ expected exercise and post-vesting employment termination behaviors. The expected stock price volatility is estimated using Company historical volatility in deriving the expected volatility assumption . The Company made an assessment that Company historic volatility is most representative of future stock price trends. The expected dividend yield is based on the estimated annual dividends that are expected to be paid over the expected life of the options as a percentage of the market value of the Company’s common stock as of the grant date. The risk-free interest rate for the expected life of the options granted is based on the United States Treasury yield curve in effect as of the grant date. The Company records stock-based compensation net of estimated forfeitures. 
Contingencies	Contingencies  The Company accounts for contingencies in accordance with ASC 450 Contingencies (“ASC 450”) which requires that an estimated loss from a loss contingency be accrued when (i) information available prior to issuance of the financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and (ii) when the amount of the loss can be reasonably estimated. Accounting for contingencies such as legal and contract dispute matters requires the use of management’s judgment. Management believes that the Company’s accruals for these matters are adequate. Nevertheless, the actual loss from a loss contingency might differ from management’s estimates.
Income Taxes	Income Taxes  The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and the tax bases of assets and liabilities using the current tax laws and rates. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts more likely than not expected to be realized.  ASC Topic 740, Accounting for Uncertainty in Income Taxes clarifies the accounting for uncertainty in income taxes recognized in the financial statements and provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. This interpretation also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, and disclosure.  The Company recognizes interest and penalties related to unrecognized tax benefits within the interest expense line and other expense line, respectively, in the Consolidated Statements of Operations. Accrued interest and penalties are included within the related liability lines in the Consolidated Balance Sheets. 
Net Loss Per Share	Net Loss Per Share  Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock adjusted for the dilutive effect of common stock equivalent shares outstanding during the period. Common stock equivalents consist of stock options, restricted stock units and stock warrants. Common equivalent shares are excluded from the computation in periods in which they have an anti-dilutive effect on earnings per share.
Fair Value Of Financial Instruments	Fair Value of Financial Instruments  Financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and debt. The estimated fair value of financial instruments has been determined using available market information or other appropriate valuation methodologies. However, considerable judgment is required in interpreting market data to develop estimates of fair value; therefore, the estimates are not necessarily indicative of the amounts that could be realized or would be paid in a current market exchange. The effect of using different market assumptions and/or estimation methodologies may be material to the estimated fair value amounts. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are at cost, which approximates fair value due to the short maturity of those instruments. The carrying value of debt approximates fair value due to its interest rate approximating market rates of interest available to the Company for similar instruments. 
Segment Reporting	Segment Reporting  The Company’s chief operating decision maker evaluates the business on a consolidated basis and therefore, the Company operates one operating and reportable segment.

Property And Equipment (Tables)

Property And Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property And Equipment [Abstract]
Components Of Property And Equipment	   December 31,  (in thousands) 2020 2019  Machinery and equipment $ 1,094 $ 841  Demonstration equipment 17 16  Computer equipment and software 1,194 1,094  Furniture and fixtures 154 144  Leasehold improvements 701 639  Gross property and equipment 3,160 2,734  Accumulated depreciation and amortization (2,577) (2,381)  Property and equipment, net $ 583 $ 353 

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Accrued Liabilities [Abstract]
Components Of Accrued Liabilities	   December 31,  (in thousands) 2020 2019  Payroll and benefits related expenses $ 1,874 $ 1,229  Collaboration and research agreements expenses 616 350  Professional services 803 679  Other accrued liabilities 325 330  Total accrued liabilities $ 3,618 $ 2,588 

Commitments, Contingencies An_2

Commitments, Contingencies And Debt (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments, Contingencies And Debt [Abstract]
Schedule of Long-term Debt	  Year Ended  December 31,  2020 2019  (in thousands)  DECD loan $ 3,070 $ 1,292  PPP loan 1,006 -  Total debt 4,076 1,292  Less: Current portion (999) (193)  Total long-term debt 3,077 1,099 
Annual Amounts of Future Minimum Principal Payments Under Certain Contractual Obligations	  Payments Due by Period  (in thousands) Total 2021 2022 2023 2024 2025 Thereafter  DECD Loan 3,088 508 564 576 588 599 253  Total $ 3,088 $ 508 $ 564 $ 576 $ 588 $ 599 $ 253 
Expense Associated with Operating Leases	  Year Ended December 31  Lease Cost Classification 2020 2019  Operating rent expense  Cost of revenue $ 71 $ 38  Research and development 50 11  Sales and marketing 29 35  General and administrative 66 46  Variable rent expense  Cost of revenue $ 7 $ 49  Research and development 1 14  Sales and marketing 45 41  General and administrative 54 57 
Future Lease Payments Related to Operating Leases	    2021 $ 63  2022 95  2023 106  2024 116  2025 123  2026 64  Total Operating Lease Payments 567  Less: Interest (135)  Present Value of Lease Liabilities $ 432 
Weighted-Average Lease Term and Discount Rate	  Weighted-average remaining lease term (in years) 5.5  Weighted-average discount rate 9.38% 

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Loss Per Share [Abstract]
Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share	   Loss Shares Per Share  (In thousands, except shares and per share data) (Numerator) (Denominator) Amount  Year ended December 31, 2019:  Net loss available to common shareholders - basic $ (15,237) 86,595,581 $ (0.18)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss available to common shareholders - diluted $ (15,237) 86,595,581 $ (0.18)   Year ended December 31, 2020:  Net loss available to common shareholders - basic $ (17,905) 100,723,303 $ (0.18)  Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards - -  Net loss available to common shareholders - diluted $ (17,905) 100,723,303 $ (0.18) 
Potential Shares Of Common Stock Excluded From Diluted Loss Per Share Calculation	   Year Ended December 31,  2020 2019  Stock options 8,212,112 6,612,878  Stock warrants - 2,810,338  Unvested restricted stock awards - -  Potential common shares 8,212,112 9,423,216 

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2020
Employee Benefit Plans [Abstract]
Activity Related to Shares Available for Grant Under the 2000 Plan and 2010 Plan	   2010 Stock Option Plan 2019 Stock Option Plan Total  Shares available at December 31, 2018 5,178,819 - 5,178,819  Shares added - 8,000,000 8,000,000  Shares transferred (2,492,283) 2,492,283 -  Options canceled 691,025 - 691,025  Options granted (2,504,585) (207,000) (2,711,585)  Restricted stock units granted (202,576) - (202,576)  Shares available at December 31, 2019 670,400 10,285,283 10,955,683   Options canceled 718,500 502,000 1,220,500  Options granted - (3,925,409) (3,925,409)  Restricted stock units granted - (356,940) (356,940)  Shares forfeited (1,388,900) - (1,388,900)  Shares available at December 31, 2020 - 6,504,934 6,504,934 
Stock Option Activity Under 2010 Plan and 2019 Plan	   Number of Shares Weighted Average Exercise Price Aggregate Intrinsic Value Weighted Average Remaining Contractual Term  Options outstanding at December 31, 2018 4,612,005 $ 1.67 $ - 7.17  Granted 2,711,585 1.02  Exercised (19,687) 1.32  Canceled (691,025) 1.79  Options outstanding at December 31, 2019 6,612,878 $ 1.67 $ 303,995 8.66  Granted 3,925,409 1.46  Exercised (1,105,675) 1.48  Canceled (1,220,500) 0.75  Options outstanding at December 31, 2020 8,212,112 $ 1.49 $ 42,833,712 7.51   Shares exercisable:  December 31, 2020 3,743,698 $ 1.56 $ 19,272,201 6.41  Shares expected to vest:  December 31, 2020 4,468,414 $ 1.44 $ 23,561,533 8.91 
Range of Exercise Prices for Options Outstanding and Exercisable	   Exercise Price Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Life in Years Options Exercisable Weighted Average Exercise Price  $ 0.47 - $ 0.68 2,157,468 $ 0.64 8.59 613,968 $ 0.61  0.71 - 1.29 3,012,383 1.11 7.93 1,039,133 1.18  1.31 - 2.83 2,102,197 1.87 5.64 1,750,572 1.80  2.87 - 4.80 940,064 3.88 7.84 340,025 3.23   $ 0.47 - $ 4.80 8,212,112 $ 1.49 7.51 3,743,698 $ 1.56  
Fair Value of Options Vested	   (in thousands) Total Intrinsic Value of Options Exercised Total Fair Value of Vested Options  Year ended December 31, 2020 $ 3,439 $ 3,254  Year ended December 31, 2019 $ 8 $ 2,869 
Assumptions Used to Calculate Fair Value of Options Granted Under 2010 Plan	   Year Ended December 31,  2020 2019  Dividend yield - % - %  Volatility 84 % 79 %  Risk-free interest rate 0.71 % 2.30 %  Expected lives (years) 2.9 4.0  Weighted average grant date fair value $ 0.87 $ 0.55 
Allocation of Employee and Director Stock-Based Compensation Expense by Functional Area	   Year Ended December 31,  (in thousands) 2020 2019  Cost of sales $ 96 $ 67  Research and development 33 4  Sales and marketing 162 122  General and administrative 924 942  Total $ 1,215 $ 1,135 

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Taxes [Abstract]
Components Of Deferred Tax Assets (Liabilities)	   Year Ended December 31,  (in thousands) 2020 2019  Deferred tax assets:  Net operating losses $ 32,740 $ 28,939  Amortization - R&D intangibles 2,495 2,810  Other - 124  Total deferred tax assets 35,235 31,873  Valuation allowance (35,195) (31,873)  Deferred tax assets $ 40 $ -   Deferred tax liabilities:  Other $ 40 $ -  Deferred tax liabilities $ 40 $ -   Net deferred tax asset $ - $ - 
Reconciliation Of Statutory Federal Income Tax Rate	   Year Ended December 31,  2020 2019  Tax at federal statutory rate 21 % 21 %  State tax, net of federal benefit 1 1  Valuation allowance (19) (42)  Net operating loss and tax credit carryforwards (2) 23  Permanent items (1) (1)  Other - (2)  Effective income tax rate - % - % 
Reconciliation Of Change In Unrecognized Tax Benefits	   (in thousands) Federal Tax State Tax Total  Balance at December 31, 2018 $ 5,637 $ 5,330 $ 10,967  Return to provision true up (210) - (210)  Increase in tax position during 2019 - 21 21  Decrease due to expirations during 2019 (134) - (134)  Balance at December 31, 2019 $ 5,293 $ 5,351 $ 10,644  Return to provision true up - - -  Increase in tax position during 2020 20 45 65  Decrease due to expirations during 2020 (192) - (192)  Balance at December 31, 2020 $ 5,121 $ 5,396 $ 10,517 

Basis Of Presentation And Sum_3

Basis Of Presentation And Summary Of Significant Accounting And Reporting Policies (Details)

Feb. 08, 2021USD ($)

Dec. 03, 2020USD ($)

Jul. 20, 2020USD ($)

Jul. 02, 2019USD ($)

Jun. 28, 2019USD ($)

Jan. 01, 2019USD ($)contract

Apr. 15, 2016USD ($)

Mar. 22, 2016USD ($)employee

Jun. 30, 2020USD ($)

Dec. 31, 2020USD ($)segment

Dec. 31, 2019USD ($)country

May 01, 2020USD ($)

Apr. 10, 2020USD ($)

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Operating lease right-of-use assets

$ 406,000

$ 52,000

Operating lease liability

432,000

Accumulated deficit

(440,066,000)

(422,161,000)

Proceeds from development loan

2,000,000

Proceeds from exercise of warrants

5,060,000

Patent costs

$ 322,000

$ 203,000

Number of reportable segments | segment

1

CARES Act [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Proceeds from stimulus check received pursuant to the CARES Act

$ 89,000

Accounting Standards Update 2016-02 [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Number of operating office leases | contract

2

Operating lease right-of-use assets

$ 178,000

Operating lease liability

178,000

Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2016-02 [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Accumulated deficit

$ 0

DECD [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

DECD maximum borrowing capacity

$ 4,000,000

Proceeds from development loan

$ 2,000,000

$ 2,000,000

DECD [Member] | Loan Agrement [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Line of credit fixed interest rate

2.00%

Line of credit, maturity date

Apr. 15, 2026

DECD maximum borrowing capacity

$ 4,000,000

Proceeds from development loan

2,000,000

$ 2,000,000

Maximum loan forgiveness amount under loan agreement

$ 1,500,000

Number of full time employees expected to be retained under loan agreement | employee

25

Consecutive period full times employees with specified average annual salary under loan agreement

2 years

Percentage of penality on total loan fund included in loan agreement

5.00%

BBVA USA [Member] | CARES Act [Member] | PPP Loan [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Aggregate amount of loan

$ 1,005,767

Loan Agreement Target Employment Milestone [Member] | DECD [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Proceeds from development loan

1,000,000

Loan Agreement Target Employment Milestone [Member] | DECD [Member] | Loan Agrement [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Proceeds from development loan

1,000,000

Loan Agreement Required Revenue Target [Member] | DECD [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Proceeds from development loan

1,000,000

Loan Agreement Required Revenue Target [Member] | DECD [Member] | Loan Agrement [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Proceeds from development loan

$ 1,000,000

2017 Private Placement [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Proceeds from exercise of warrants

$ 5,058,608

2019 Offerings [Member] | Common Stock [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Proceeds from public offering

$ 2,092,000

$ 13,521,000

2019 Offerings [Member] | Common Stock [Member] | William Blair & Company, L.L.C [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Proceeds from public offering

$ 13,521,000

2020 Private Placement [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Net proceeds from issuance of private placement

$ 10,600,000

2021 Offerings [Member] | Subsequent Event [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Proceeds from public offering

$ 48,400,000

Minimum [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Number of countries novel coronavirus has spread | country

100

Property and equipment useful life

3 years

Maximum [Member]

Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]

Property and equipment useful life

5 years

Strategic Alliance With Quest_2

Strategic Alliance With Quest Diagnostics Incorporated (Details) $ in Thousands	Mar. 11, 2020USD ($)
Quest Diagnostics [Member] | Amended Agreement [Member]
Line of Credit Facility [Line Items]
Annual fee to services of Part-time Quest Diagnostics project manager	$ 75

Property And Equipment (Narrati

Property And Equipment (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property And Equipment [Abstract]
Depreciation expense for property and equipment	$ 265	$ 333

Property And Equipment (Compone

Property And Equipment (Components Of Property And Equipment) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 3,160	$ 2,734
Accumulated depreciation and amortization	(2,577)	(2,381)
Property and equipment, net	583	353
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	1,094	841
Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	17	16
Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	1,194	1,094
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	154	144
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 701	$ 639

Accrued Liabilities (Components

Accrued Liabilities (Components Of Accrued Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accrued Liabilities [Abstract]
Payroll and benefits related expenses	$ 1,874	$ 1,229
Collaboration and research agreements expenses	616	350
Professional services	803	679
Other accrued liabilities	325	330
Total accrued liabilities	$ 3,618	$ 2,588

Commitments, Contingencies An_3

Commitments, Contingencies And Debt (Narrative) (Details)	Dec. 03, 2020USD ($)	Apr. 15, 2016USD ($)	Mar. 22, 2016USD ($)employee	Dec. 31, 2020USD ($)item	Dec. 31, 2019USD ($)	May 01, 2020USD ($)	Oct. 31, 2015USD ($)
Commitments And Contingencies [Line Items]
Proceeds from development loan				$ 2,000,000
Royalty expense				$ 181,000	$ 176,000
Austin, Texas Facility [Member]
Commitments And Contingencies [Line Items]
Lease renewal term				1 year
Trumbull, Connecticut Facility [Member]
Commitments And Contingencies [Line Items]
Leasehold improvements							$ 596,000
Lease expiration date				Jun. 30, 2026
Lease renewal term				5 years
DECD Loan [Member]
Commitments And Contingencies [Line Items]
Debt issuance costs				$ 18,000
PPP Loan [Member]
Commitments And Contingencies [Line Items]
Debt instrument carrying amount				$ 1,000,000
Insurance Promissory Notes [Member]
Commitments And Contingencies [Line Items]
Debt instrument interest rate				3.88%	4.49%
Aggregate principal amount outstanding				$ 611,000	$ 303,000
Cancelable insurance promissory note				$ 611,000
Notes payable number of monthly payment installment | item				10
Johns Hopkins University School Of Medicine [Member]
Commitments And Contingencies [Line Items]
Percent of royalty paid				4.00%
Minimum royalty payment				$ 57,500
BBVA USA [Member] | CARES Act [Member] | PPP Loan [Member]
Commitments And Contingencies [Line Items]
Aggregate amount of loan						$ 1,005,767
BBVA USA [Member] | CARES Act [Member] | PPP Loan [Member] | Unforgiven Portion Of PPP Loan [Member]
Commitments And Contingencies [Line Items]
Debt instrument interest rate						1.00%
DECD [Member]
Commitments And Contingencies [Line Items]
DECD maximum borrowing capacity			$ 4,000,000
Proceeds from development loan	$ 2,000,000	$ 2,000,000
DECD [Member] | Loan Agreement Target Employment Milestone [Member]
Commitments And Contingencies [Line Items]
Proceeds from development loan	1,000,000
DECD [Member] | Loan Agreement Required Revenue Target [Member]
Commitments And Contingencies [Line Items]
Proceeds from development loan	1,000,000
DECD [Member] | Loan Agrement [Member]
Commitments And Contingencies [Line Items]
DECD maximum borrowing capacity			$ 4,000,000
Line of credit fixed interest rate			2.00%
Line of credit, maturity date				Apr. 15, 2026
Proceeds from development loan	2,000,000	$ 2,000,000
Maximum loan forgiveness amount under loan agreement			$ 1,500,000
Number of full time employees expected to be retained under loan agreement | employee			25
Consecutive period full times employees with specified average annual salary under loan agreement			2 years
Percentage of penality on total loan fund included in loan agreement			5.00%
DECD [Member] | Loan Agrement [Member] | Loan Agreement Target Employment Milestone [Member]
Commitments And Contingencies [Line Items]
Proceeds from development loan	1,000,000
DECD [Member] | Loan Agrement [Member] | Loan Agreement Required Revenue Target [Member]
Commitments And Contingencies [Line Items]
Proceeds from development loan	$ 1,000,000

Commitments, Contingencies An_4

Commitments, Contingencies And Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Total debt	$ 4,076	$ 1,292
Less: Current portion	(999)	(193)
Total long-term debt	3,077	1,099
DECD Loan [Member]
Debt Instrument [Line Items]
Total debt	3,070	$ 1,292
PPP Loan [Member]
Debt Instrument [Line Items]
Total debt	$ 1,006

Commitments, Contingencies An_5

Commitments, Contingencies And Debt (Annual Amounts of Future Minimum Principal Payments Under Certain Contractual Obligations) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Other Commitments [Line Items]
Total debt	$ 4,076	$ 1,292
Contractual obligation, 2021	508
Contractual obligation, 2022	564
Contractual obligation, 2023	576
Contractual obligation, 2024	588
Contractual obligation, 2025	599
Contractual obligation, Thereafter	253
Total	3,088
DECD Loan [Member]
Other Commitments [Line Items]
Total debt	3,070	$ 1,292
Contractual obligation, 2021	508
Contractual obligation, 2022	564
Contractual obligation, 2023	576
Contractual obligation, 2024	588
Contractual obligation, 2025	599
Contractual obligation, Thereafter	253
Total	$ 3,088

Commitments, Contingencies An_6

Commitments, Contingencies And Debt (Expense Associated with Operating Leases) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cost Of Revenue [Member]
Operating rent expense	$ 71	$ 38
Variable rent expense	7	49
Research And Development [Member]
Operating rent expense	50	11
Variable rent expense	1	14
Sales And Marketing [Member]
Operating rent expense	29	35
Variable rent expense	45	41
General And Administrative [Member]
Operating rent expense	66	46
Variable rent expense	$ 54	$ 57

Commitments, Contingencies An_7

Commitments, Contingencies And Debt (Future Lease Payments Related to Operating Leases) (Details) $ in Thousands	Dec. 31, 2020USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2021	$ 63
2022	95
2023	106
2024	116
2025	123
2026	64
Total Operating Lease Payments	567
Less: Interest	(135)
Present Value of Lease Liabilities	$ 432

Commitments, Contingencies An_8

Commitments, Contingencies And Debt (Weighted-Average Lease Term and Discount Rate) (Details)	Dec. 31, 2020
Leases [Abstract]
Weighted-average remaining lease term (in years)	5 years 6 months
Weighted-average discount rate	9.38%

Common Stock (Details)

Common Stock (Details) - USD ($)	Jul. 20, 2020	Jun. 09, 2020	Jul. 02, 2019	Jun. 28, 2019	Feb. 17, 2017	Dec. 31, 2020	Dec. 31, 2019	Jun. 26, 2019
Common Stock Equity [Line Items]
Common stock, par value						$ 0.001	$ 0.001
Common stock, shares issued						104,619,876	97,286,157
Proceeds from exercise of warrants						$ 5,060,000
Common stock value						$ 105,000	$ 97,000
2020 Private Placement [Member] | Common Stock [Member]
Common Stock Equity [Line Items]
Common stock, shares issued	3,150,000
Common stock share price	$ 3.50
Net proceeds from public offering	$ 10,600,000
Private Placement [Member] | Common Stock [Member]
Common Stock Equity [Line Items]
Costs related to issuance of common stock	$ 384,000
2019 Offerings [Member] | Common Stock [Member]
Common Stock Equity [Line Items]
Net proceeds from public offering			$ 2,092,000	$ 13,521,000
2019 Offerings [Member] | William Blair & Company, L.L.C [Member] | Common Stock [Member]
Common Stock Equity [Line Items]
Underwriting agreement, shares								18,750,000
Common stock, par value								$ 0.001
Common stock, shares issued				18,750,000
Common stock share price				$ 0.80
Net proceeds from public offering				$ 13,521,000
Costs related to issuance of common stock				$ 1,500,000
2019 Offerings [Member] | William Blair & Company, L.L.C [Member] | Over-Allotment Option [Member] | Common Stock [Member]
Common Stock Equity [Line Items]
Common stock, shares issued			2,812,500
Common stock share price			$ 0.80
Net proceeds from public offering			$ 2,092,000
2020 Exercise of Warrants [Member]
Common Stock Equity [Line Items]
Common stock, shares issued		2,810,338
Exercise price of warrants					$ 1.80
Initially sold price per share					$ 0.125
Proceeds from exercise of warrants		$ 5,060,000
Maximum [Member] | 2019 Offerings [Member] | William Blair & Company, L.L.C [Member] | Over-Allotment Option [Member] | Common Stock [Member]
Common Stock Equity [Line Items]
Underwriting agreement, shares								2,812,500
Maximum [Member] | 2020 Exercise of Warrants [Member]
Common Stock Equity [Line Items]
Warrants issued to purchase common stock					2,810,338

Loss Per Share (Reconciliation

Loss Per Share (Reconciliation Of Numerators And Denominators Of Basic And Diluted Loss Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Loss (Numerator)
Net loss available to common shareholders - basic	$ (17,905)	$ (15,237)
Dilutive effect of common stock shares issuable upon exercise of stock options, exercise of warrants, and unvested restricted stock awards
Net loss available to common shareholder - diluted	$ (17,905)	$ (15,237)
Shares (Denominator)
Net loss available to common shareholders - basic	100,723,303	86,595,581
Net loss available to common shareholder - diluted	100,723,303	86,595,581
Per Share Amount
Net loss available to common shareholders - basic	$ (0.18)	$ (0.18)
Net loss available to common shareholder - diluted	$ (0.18)	$ (0.18)

Loss Per Share (Potential Share

Loss Per Share (Potential Shares Of Common Stock Excluded From Diluted Loss Per Share Calculation) (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	8,212,112	9,423,216
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	8,212,112	6,612,878
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share		2,810,338

Employee Benefit Plans (Narrati

Employee Benefit Plans (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	6,504,934	10,955,683	5,178,819
401(k) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
401(k) Plan, percentage for employee maximum contribution amount	90.00%
401(k) employer contributions	$ 0	$ 0
Unvested Stock Option Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation costs related to nonvested stock option awards	$ 2,970,000
Weighted average period over which unrecognized cost expected to be recognized	2 years 8 months 19 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation costs related to nonvested stock option awards	$ 0
2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	10,492,283
Share based compensation shares authorized for grants	10,492,283
Common Stock Subject to Outstanding Stock Options [Member] | 2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	4,776,503
Common Stock Subject to Outstanding Stock Options [Member] | 2019 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	3,442,109
Common Stock Subject to Outstanding Stock Options [Member] | 2019 Stock Incentive Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation shares reserved for issuance	0

Employee Benefit Plans (Activit

Employee Benefit Plans (Activity Related to Shares Available for Grant Under the 2010 Plan and 2019 Plan) (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period	10,955,683	5,178,819
Shares added		8,000,000
Options canceled	1,220,500	691,025
Options. granted	(3,925,409)	(2,711,585)
Restricted stock units granted	(356,940)	(202,576)
Options forfeited	(1,388,900)
Shares available at end of period	6,504,934	10,955,683
2010 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period	670,400	5,178,819
Shares transferred		(2,492,283)
Options canceled	718,500	691,025
Options. granted		(2,504,585)
Restricted stock units granted		(202,576)
Options forfeited	(1,388,900)
Shares available at end of period		670,400
2019 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available at beginning of period	10,285,283
Shares added		8,000,000
Shares transferred		2,492,283
Options canceled	502,000
Options. granted	(3,925,409)	(207,000)
Restricted stock units granted	(356,940)
Options forfeited
Shares available at end of period	6,504,934	10,285,283

Employee Benefit Plans (Stock O

Employee Benefit Plans (Stock Option Activity Under 2010 Plan and 2019 Plan) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Number of Shares
Options outstanding	6,612,878	4,612,005
Granted	3,925,409	2,711,585
Exercised	(1,105,675)	(19,687)
Canceled	(1,220,500)	(691,025)
Options outstanding	8,212,112	6,612,878	4,612,005
Shares exercisable	3,743,698
Shares expected to vest	4,468,414
Weighted Average Exercise Price
Options outstanding	$ 1.67	$ 1.67
Granted	1.46	1.02
Exercised	1.48	1.32
Canceled	0.75	1.79
Opstions outstanding	1.49	$ 1.67	$ 1.67
Shares exercisable	1.56
Shares expected to vest	$ 1.44
Aggregate Intrinsic Value
Options outstanding	$ 42,833,712	$ 303,995
Shares exercisable	19,272,201
Shares expected to vest	$ 23,561,533
Weighted Average Remaining Contractual Term
Options outstanding	7 years 6 months 4 days	8 years 7 months 28 days	7 years 2 months 1 day
Shares exercisable	6 years 4 months 28 days
Shares expected to vest	8 years 10 months 28 days

Employee Benefit Plans (Range o

Employee Benefit Plans (Range of Exercise Prices for Options Outstanding and Exercisable) (Details)	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	$ 0.47
Exercise Price Upper Range	$ 4.80
Options Outstanding | shares	8,212,112
Weighted Average Exercise Price	$ 1.49
Weighted Average Remaining life	7 years 6 months 4 days
Options Exercisable | shares	3,743,698
Weighted Average Exercise Price	$ 1.56
Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	0.47
Exercise Price Upper Range	$ 0.68
Options Outstanding | shares	2,157,468
Weighted Average Exercise Price	$ 0.64
Weighted Average Remaining life	8 years 7 months 2 days
Options Exercisable | shares	613,968
Weighted Average Exercise Price	$ 0.61
Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	0.71
Exercise Price Upper Range	$ 1.29
Options Outstanding | shares	3,012,383
Weighted Average Exercise Price	$ 1.11
Weighted Average Remaining life	7 years 11 months 5 days
Options Exercisable | shares	1,039,133
Weighted Average Exercise Price	$ 1.18
Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	1.31
Exercise Price Upper Range	$ 2.83
Options Outstanding | shares	2,102,197
Weighted Average Exercise Price	$ 1.87
Weighted Average Remaining life	5 years 7 months 21 days
Options Exercisable | shares	1,750,572
Weighted Average Exercise Price	$ 1.80
Range Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Lower Range	2.87
Exercise Price Upper Range	$ 4.80
Options Outstanding | shares	940,064
Weighted Average Exercise Price	$ 3.88
Weighted Average Remaining life	7 years 10 months 2 days
Options Exercisable | shares	340,025
Weighted Average Exercise Price	$ 3.23

Employee Benefit Plans (Fair Va

Employee Benefit Plans (Fair Value of Options Vested) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Employee Benefit Plans [Abstract]
Total Intrinsic Value of Options Exercised	$ 3,439	$ 8
Total Fair Value of Vested Options	$ 3,254	$ 2,869

Employee Benefit Plans (Assumpt

Employee Benefit Plans (Assumptions Used to Calculate Fair Value of Options Granted Under 2010 Plan) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Employee Benefit Plans [Abstract]
Dividend yield
Volatility	84.00%	79.00%
Risk-free interest rate	0.71%	2.30%
Expected lives (years)	2 years 10 months 24 days	4 years
Weighted average grant date fair value	$ 0.87	$ 0.55

Employee Benefit Plans (Allocat

Employee Benefit Plans (Allocation of Employee and Director Stock-Based Compensation Expense by Functional Area) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 106	$ 78
Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	34	4
Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	228	125
General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,180	986
Employee Stock-based Compensation [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,215	1,135
Employee Stock-based Compensation [Member] | Cost Of Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	96	67
Employee Stock-based Compensation [Member] | Research And Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	33	4
Employee Stock-based Compensation [Member] | Sales And Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	162	122
Employee Stock-based Compensation [Member] | General And Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 924	$ 942

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Taxes [Line Items]
Net overstatement of deferred tax assets	$ 2,641,350
Income tax benefit (expense)	0	$ 0
Domestic and foreign components of loss from continuing operations before income taxes	17,905,000	15,236,000
Valuation allowance	35,195,000	31,873,000
Interest and penalties as a result of uncertain tax positions	0	0
Gross unrecognized tax benefits	10,517,000	10,644,000	$ 10,967,000
Research and Development Credits [Member]
Income Taxes [Line Items]
Operating loss carryforwards	5,292,000	5,351,000
Gross unrecognized tax benefits	10,517,000
Total Unrecognized income tax benefit, affecting effective tax rate if recognized	10,500,000
Federal Tax [Member]
Income Taxes [Line Items]
Increase in valuation allowance	3,300,000
Gross unrecognized tax benefits	5,121,000	$ 5,293,000	$ 5,637,000
Portions of Net Operating Loss Excluded from Deferred Tax Assets [Member]
Income Taxes [Line Items]
Understatement of deferred tax assets	5,535,246
Deferred State Income Taxes Not Recorded [Member]
Income Taxes [Line Items]
Understatement of deferred tax assets	2,466,759
Tax Credit Carryovers Incorrectly Reflected [Member]
Income Taxes [Line Items]
Overstatement of deferred tax assets	$ 10,643,355
Federal NOLs Arising Before January 1, 2018 [Member]
Income Taxes [Line Items]
Percentage of future taxable income that can be Offsetted	100.00%
Federal NOLs Arising After January 1, 2018 [Member]
Income Taxes [Line Items]
Percentage of future taxable income that can be Offsetted	80.00%
Additional [Member] | Federal Tax [Member] | Research and Development Credits [Member]
Income Taxes [Line Items]
Operating loss carryforwards	$ 20,000
Additional [Member] | California State [Member] | Research and Development Credits [Member]
Income Taxes [Line Items]
Operating loss carryforwards	$ 45,000

Income Taxes (Components Of Def

Income Taxes (Components Of Deferred Tax Assets (Liabilities)) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating losses	$ 32,740	$ 28,939
Amortization - R&D intangibles	2,495	2,810
Other		124
Total deferred tax assets	35,235	31,873
Valuation allowance	(35,195)	(31,873)
Deferred tax assets	40
Deferred tax liabilities:
Other	40
Deferred tax liabilities	40
Net deferred tax asset

Income Taxes (Reconciliation Of

Income Taxes (Reconciliation Of Statutory Federal Income Tax Rate) (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Taxes [Abstract]
Tax at federal statutory rate	21.00%	21.00%
State tax, net of federal benefit	1.00%	1.00%
Valuation allowance	(19.00%)	(42.00%)
Net operating loss and tax credit carryforwards	(2.00%)	23.00%
Permanent items	(1.00%)	(1.00%)
Other		(2.00%)
Effective Income Tax Rate Reconciliation, Percent, Total

Income Taxes (Reconciliation _2

Income Taxes (Reconciliation Of Change In Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Contingency [Line Items]
Beginning Balance	$ 10,644	$ 10,967
Return to provision true up		(210)
Increase in tax position	65	21
Decrease due to expirations	(192)	(134)
Ending Balance	10,517	10,644
Federal Tax [Member]
Income Tax Contingency [Line Items]
Beginning Balance	5,293	5,637
Return to provision true up		(210)
Increase in tax position	20
Decrease due to expirations	(192)	(134)
Ending Balance	5,121	5,293
State and Local Jurisdiction
Income Tax Contingency [Line Items]
Beginning Balance	5,351	5,330
Return to provision true up
Increase in tax position	45	21
Decrease due to expirations
Ending Balance	$ 5,396	$ 5,351

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	Feb. 08, 2021	Feb. 04, 2021	Dec. 31, 2020	Dec. 31, 2019
Subsequent Event [Line Items]
Common stock, par value			$ 0.001	$ 0.001
William Blair & Company, L.L.C. and Truist Securities, Inc. [Member]William Blair And Company Llc And Truist Securities Inc [Member] | Subsequent Event [Member] | 2021 Underwriting Agreement [Member]
Subsequent Event [Line Items]
Underwriting agreement, shares		6,000,000
Common stock, par value		$ 0.001
Common stock share price		7.50
Underwriting discount per share		$ 0.4875
Net proceeds from public offering	$ 48.4
William Blair & Company, L.L.C. and Truist Securities, Inc. [Member]William Blair And Company Llc And Truist Securities Inc [Member] | Subsequent Event [Member] | 2021 Underwriting Agreement [Member] | Over-Allotment Option [Member]
Subsequent Event [Line Items]
Underwriting agreement, shares		900,000
William Blair & Company, L.L.C. and Truist Securities, Inc. [Member]William Blair And Company Llc And Truist Securities Inc [Member] | Subsequent Event [Member] | 2021 Option Shares [Member] | Over-Allotment Option [Member]
Subsequent Event [Line Items]
Common stock, par value		$ 0.001
Underwriting discount per share		$ 0.4875